

Spring 2016

Inside This Issue

President's Message
Qualified Person Training Program
RPSC-Sponsored Sessions and Events
2016 Board of Directors Election – Meet the Candidates

President's Message

Suzanne Lapi, PhD, RPSC President



Dear of Radiopharmaceutical Sciences Council (RPSC) membership,

It's been a pleasure to serve the radiopharmaceutical community for this last year as RPSC president. I would like to take this opportunity to thank you all for your continued support and active participation in the operation of the RPSC and our continued scientific programming during the last year. Also, I would like to thank our Annual Poster Mixer event sponsors who contributed generously in order to make this event a success.

I am looking forward to the Society of Nuclear Medicine and Molecular Imaging 63rd annual meeting in San Diego and to continuing to work with Shawn Chen, PhD, incoming president for the term 2016-2017, as well as the other RPSC board members, during the coming years.

RPSC continues to be effective in responding to ever-changing scientific focuses and regulatory environment through the help and support provided by our members. In particular, we have supported a new initiative led by Sally Schwarz, incoming president of the SNMMI, to work toward the formation of the Qualified Person Training Program (QPTP). More information on this program can be found later in this newsletter. We also have expanded on our continuing education (CE) sessions for 2016 and welcome feedback on this and potential future programming.

RPSC will present several awards this year to recognize scientific contributions from members in the field of radiopharmaceutical sciences including:

- **Michael J. Welch Award:** The recipient of this award is Dr. Robert Dannals, PhD of the Johns Hopkins PET Center in Baltimore MD.
- **Berson-Yalow Award:** The award will be announced shortly and is presented for the most original scientific contribution that impacts basic or clinical radioassays.
- **Young Investigator Awards:** For the tenth consecutive year, promising young scientists will be presented with awards and travel funding, in a continuing effort to encourage participation in the annual meeting by talented trainees and new investigators.

RPSC and CMIIT are once again co-sponsoring a [Poster Session Mixer](#) at the 2016 SNMMI annual meeting in San Diego, CA. This poster mixer will take place on Sunday, June 12 from 6:30pm – 8:30pm in Exhibit Hall G of

the San Diego Convention Center and will encourage poster attendance and stimulation of RPSC membership. The council would like to thank our generous [sponsors](#).

I am also pleased to announce the 2016 election for new officers (vice president-elect and secretary) and new members of the RPSC Board of Directors. Beginning on the next page, you will find biographical sketches and statements from RPSC members who have accepted nominations and volunteered their time to participate in this year's election.

Please read the candidate information and select the individuals whom you feel will best represent your interests in council matters. Write-in candidates are permitted. All voting members of the RPSC will receive an email notification when the elections open in April.

If you are attending the SNMMI Annual Meeting in San Diego this June 11-15, you will see the diversity of scientific and educational offerings. Please browse the [SNMMI Annual Meeting website](#) to see the full list of RPSC-sponsored programs and other sessions of interest. As a RPSC member, you are invited to participate in the RPSC business meeting on Sunday, June 12 from 6:00pm – 6:30pm (room TBA) at the San Diego Convention Center. I am looking forward to seeing you there.

Suzanne Lapi, PhD
President, RPSC
Associate Professor of Radiology
University of Alabama at Birmingham

Qualified Person Training Program

A Qualified Person Training Program is being developed through the SNMMI, which will train radiopharmacists and radiochemists in the areas required for the release of manufactured radiopharmaceuticals. This type of education requires that a program be developed to address theoretical knowledge and practical experience needed to assume responsibility for production, quality control and release of radiopharmaceuticals. Specific needs include aseptic technique training, media fill testing, production (including synthesis and pharmaceutical formulation from both cyclotron and reactor produced radionuclides) and quality control of radiopharmaceuticals for both academic and commercial settings. Additionally, regulatory compliance with FDA regulations (Part 211 and Part 212) and USP requirements, including Chapters <823> and <797>, dosimetry and applications of radiopharmaceuticals in clinical nuclear medicine and therapy.

At the current time there are insufficient individuals with this type of training and it would benefit both academic and commercial entities by providing these trained individuals. The didactic training would be provided by modular courses which would be available for anyone who wanted to take them, even if they did not want to take the entire course. Experiential training would require 4-6 weeks of hands-on training in methodology instrumentation appropriate for both diagnostic and therapeutic radiopharmaceuticals, and interpretation of testing results. Additionally, a certification exam would be established for the program through the SNMMI. It would be similar to the Qualified Person program in the EU that is managed through the EANM.

The RPSC intern will be involved in the development of the courses for the program

2016 Annual Meeting RPSC Sponsored Sessions

Categorical Session

[Small Molecule PET Radiotracers](#) - Saturday, June 11, 8:00 am-4:00 pm, Room 30C

CE Sessions:

[Theranostic Nanoparticles](#) – Sunday, June 12, 2:45-4:15 pm, Room 33A

[Next-Generation Radiotracers for Cancer Imaging](#) – Saturday, June 11, 4:30-6:00 pm, Room 33A

[Career Boot Camp: The Cliff Note Guide to Navigating Your Career Success](#) – Sunday, June 12, 4:30-6:00 pm
Room 32B

[Michael J. Welch Award and Lecture](#) – Monday, June 13, 12:30-2:00 pm, Room 33A

[Bioorthogonal and Click Chemistry for Molecular Imaging/Therapy](#) – Monday, June 13, 3:00-4:30 pm, Room
33A

[Saul Hertz Award Symposium: Theranostics](#) – Monday, June 13, 4:45-6:15 pm, Room 32B

[From Molecule to Man: Translation of Tracers in Europe, United States and China](#) - Tuesday, June 14, 10:00-
11:30 am, Room 32B

[New Targets: Tracer and Techniques in Nuclear Cardiology](#) - Tuesday, June 14, 12:30-2:00 pm, Room 33C

[PET Drug Manufacturing: Living in an FDA-Regulated World](#) –Tuesday, June 14, 12:30-2:00 pm, Room 20BC

2016 Annual Meeting RPSC Events

RPSC Business Meeting - Open to all RPSC members, Sunday, June 12, 6:00-6:30 pm, Room TBD

RPSC Board of Directors Meeting – Monday, June 13, 11:30 am- 12:30 pm (closed for Board Members only),
Room TBD

RPSC Young Investigators Award Symposium - The RPSC Young Investigator Symposium will be held on
Sunday, June 12, 12:30-2:00 pm.

Radiopharmaceutical Sciences/Molecular Imaging/CMIIT Basic Science Summary - The Basic Science
Summary Session co-sponsored by RPSC and the Center for Molecular Imaging Innovation and Translation will
be held on Sunday, June 12, 4:30- 6:00 pm.

[RPSC/CMIIT 10th Annual Poster Mixer](#) - Please also join the 10th Annual RPSC/CMIIT Poster Mixer on
Sunday, June 12, 6:30-8:30 pm in Exhibit Halls G. Drinks and light Hors d'oeuvres will be served.

New This Year! Young Investigator Award Ceremony - Monday, June 13, 2:00-3:00 pm in Exhibit Hall G.

2016 Board of Directors Election: Meet the Candidates

Vice President-Elect

David Dick, PhD



David Dick is currently a Clinical Assistant Professor and Chief of Radionuclide Production & Clinical PET Radiochemistry at the University of Iowa. Prior to his arrival at the University of Iowa, Dr. Dick was the Head of Cyclotron Physics at Stanford University. Dr. Dick obtained his Ph.D. in Medical Physics from the University of Wisconsin-Madison under the supervision of Dr. Jerry Nickles.

Dr. Dick has been a member of the SNM and RPSC for over 15 years and is also an active member of the Society of Radiopharmaceutical Sciences, American Chemical Society and American Physical Society. He has been a member of the SNM Clinical Trials Network Manufacturer's Registry Committee since 2009 and chair of that committee since 2010. Dr. Dick is also a board member on the SNMMI PET Center of Excellence, having been elected in 2015. Dr. Dick serves as a reviewer for Applied Radiation and Isotopes, Journal of Nuclear Medicine, Medical Physics, Molecular Imaging and abstracts for the SNMMI and WMIC annual meetings.

Dr. Dick's efforts over the past nine years have been significantly focused on PET drug CGMP and the radiopharmaceutical approval process, precipitated by being the first academic site to receive a FDG surveillance inspection by the FDA in 2007. He has since worked tirelessly on advising and educating the greater PET community on the regulatory requirements for PET drugs, giving numerous invited talks and consulted with individual sites.

Dr. Dick has served two terms as Secretary of the RPSC, allowing him to have an active role in the RPSC and also put to use his skills in documentation and editing. Dr. Dick now wants to take an even more active role within the RPSC and is running for the position of Vice President-Elect. This is a unique opportunity, as Dr. Dick can leverage his committee chair within the Clinical Trials Network and board seat on the PET Center of Excellence to promote synergy between these two bodies and the RPSC, providing even more opportunity for impact within the field of radiopharmaceuticals as we continue to navigate the new rules concerning regulatory compliance and approval of new radiopharmaceuticals

Andrew G. Horti, PhD



Andrew G. Horti obtained his PhD in organic synthesis and physical chemistry at the Leningrad Institute of Technology, USSR. Subsequently he worked as a research scientist on the Anti-Cancer Drug program for the same university. In 1992, after the collapse of USSR, Andrew moved to USA, where he resided in Baltimore, MD. He completed his post-doctoral training at the Johns Hopkins University PET Center under the supervision of Drs. Henry N. Wagner, Jr. and Robert F. Dannals. Following that he worked as a PET radiochemist for the Yale University-VA PET center in West Haven, CT. His career continued at the NIDA

IRP where he was responsible for the operation of the PET radiochemistry laboratory. He is currently an Associate Professor in the Department of Radiology, Division of Nuclear Medicine at the Johns Hopkins University School of Medicine.

Dr. Horti's main scientific interest is design and development of radiotracers for emission tomography imaging. His group has pioneered the development of PET radioligands for nicotinic ($\alpha 4\beta 2$ - and $\alpha 7$ -nAChR) and

cannabinoid (CB1) receptors. Five of these PET radioligands ([18F]2-FA, [18F]AZAN, [18F]XTRA, [18F]ASEM, [11C]OMAR) have been translated by his group to human studies and are now used worldwide. These radiotracers are important tools employing PET imaging to elucidate the pathophysiology of various central and peripheral disorders and conditions. They are also useful for evaluation of new nicotinic and cannabinoid drugs. Dr. Horti's research is supported by the NIH, private foundations and the pharmaceutical industry.

Dr. Horti's scientific results have been published in various peer-reviewed journals, invited reviews and two books. He acts as a grant reviewer of funding agencies in the US, Canada and Europe. He reviews manuscripts for a number of research journals in the field of radiopharmaceutical science and molecular imaging. He also holds appointments on editorial boards for over ten scientific journals.

Dr. Horti is an active member of the Society of Nuclear Medicine and Molecular Imaging and he has organized research sessions and continued education sessions for several SNMMI meetings.

Secretary

Steven H. Liang, PhD



Steven H. Liang is an Assistant Professor of Radiology (2013-), Harvard Medical School and Member of Gordon Center for Medical Imaging, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital. (<http://scholar.harvard.edu/stevenliang>) At the University of British Columbia from 2004 to 2010, Dr. Liang received his Ph.D. training in synthetic chemistry and the total synthesis of natural products. Based on his doctoral work, he has been recognized by several national and international awards, including the Gladys Estella Laird Research Fellowship, UBC Graduate Fellowship, Chinese Oversea Excellence in Research and a prestigious Postdoctoral Award from the Natural Sciences and Engineering Research Council of Canada (NSERC).

In April 2010, Dr. Liang joined the laboratory of Nobel Laureate Prof. E.J. Corey at Harvard University. One of his contributions was the invention and commercialization of a new silyl reagent, which was highlighted in Chemical and Engineering News, Synform and was one of the most-cited articles in Organic Letters in 2011.

Dr. Liang's basic science training in the field of chemistry helps him to develop novel radiochemistry to prepare new PET probes and radiopharmaceuticals for clinical applications with 11C and 18F. His work focuses on the discovery of small molecule-based PET biomarkers for important yet underexplored neurological receptors, transporters and enzymes, and the subsequent transition of these new diagnostics into the clinic. Dr. Liang has authored > 30 publications in his current position, including several significant discoveries published in Nat. Commun. (2014), J. Nucl. Med. (two articles in 2015) & Angew. Chem. Int. Ed. (five articles 2014-2016) as the senior/corresponding author. He was honored to be the recipient of several national and international awards, including a Young Investigator Award from Alzheimer's Drug Discovery Foundation (2013), the 1st Young Investigator Award, RPSC, SNMMI (2014), the first awardee of Dr. Michael J. Welch travel grant for young scientist (2014), and other merit-based travel grants, including ACS Young Chemists Committee and CIBA foundation award (2015).

His research has also been highlighted as covers of scientific journals and featured articles in 11 different journals, as well as media coverage in Chemical and Engineering News (American Chemical Society) and The Cutting Edge of Chemistry (Thomson Reuters). Recently the patent based on his discovery of hypervalent iodine labeling technology (H.I.T.) was licensed by a pharmaceutical company to produce 18F-radiopharmaceuticals for hospital use and several products have been distributed across the country and

overseas for clinical trials (highlighted by Chemical and Engineering News 2015 and SNMMI annual meeting, Baltimore, 2015).

Being an active member of SNMMI, Dr. Liang is seeking to be elected as the Secretary for the RPSC Board of Directors. He will be responsible for meeting notifications, minutes and record keepings, and all functions to support RPSC by his office. He is also enthusiastic about the involvement in RPSC's continuing education, supporting and training students with different scientific backgrounds, as well as continues his effort to bridge basic radiopharmaceutical sciences to nuclear medicine and molecular imaging - a key and fast-growing ground for translational science and precision medicine in patient care.

Naga Vara Kishore Pillarsetty, PhD



Dr. NagaVaraKishore Pillarsetty is currently serving as Associate Attending Chemist at Memorial Sloan-Kettering Cancer Center (MSKCC), NY and Assistant Professor of Radiology at Weill Cornell Medical College, NY. He also serves as the Director of Preclinical Training and Radiochemistry in the department of Radiology at MSKCC. Dr. Pillarsetty obtained his Ph.D. in chemistry from the University of Missouri-Columbia in 2003 and carried out post-doctoral studies under the mentorship of Drs. Ronald Blasberg and Ronald Finn at MSKCC, focusing on the development of 18F- and 124I-labeled small molecules. In 2006, Dr. Pillarsetty was appointed as Assistant Attending Chemist, and promoted to Associate Attending Chemist in 2012. His research efforts are focused on the development of PET imaging probes for oncological applications, with emphasis on understanding EMT and metastatic behavior of the tumors. To date, Dr. Pillarsetty has authored more than 40

publications, 5 patent applications, and 3 review articles.

Dr. Pillarsetty has made significant contributions to different areas of radiochemistry ranging from precursor development, methodology development and clinical translation of PET probes. He was critically involved in preclinical validation studies and methodology development that have led to clinical translation of 5 different PET probes for oncological applications at MSKCC. Dr. Pillarsetty is a regular reviewer for leading journals (>15) in the fields of chemistry, nuclear medicine, and molecular imaging, including the Journal of Nuclear Medicine, Nuclear Medicine and Biology, etc..

He has been an active member of the Society of Nuclear Medicine since 2008 and was a member of the board of directors of the SNM's Young Professionals Committee from 2008-2014. If elected as a secretary of the Radiopharmaceutical Sciences Council (RPSC), Dr. Pillarsetty will strive to advance the goals of RPSC, provide a voice to the concerns and suggestions of fellow RPSC members - especially the young members of the community, devise strategies to recruit new members, and support initiatives to improve the public and scientific visibility of radiopharmaceutical sciences. Dr. Pillarsetty will also try to initiate new programs/forums in the RPSC that will encourage and facilitate interactions and collaborations within the members of the community, and, with the industry.

Board Members

Kristina M. Biederstedt, BS, CNMT



Krissy Biederstedt joined the Triad Isotopes' team in 2008, and holds the position of Market Intelligence Manager. She has been in the Radiopharmaceutical Industry since the completion of her Nuclear Medicine Technology degree, and is a certified Nuclear Medicine Technologist through the Nuclear Medicine Technology Certification Board.

As a graduate from the University of Findlay in Ohio, she has earned two Bachelor of Science degrees: Biology with an emphasis on Life Sciences, and in Nuclear Medicine Technology.

Krissy is currently active on the board of the Southeastern Michigan Associates & Technical Affiliates (SEMATA), which is an affiliate organization of the Central Chapter of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) that hosts Continuing Education seminars twice a year. She has served on SEMATA's Continuing Education Committee since 2009, as SEMATA President-Elect in 2012-2013 and 2014-2015, and as SEMATA President 2013-2014 and 2015-2016. Additionally, Krissy is a member of the SNMMI-Central Chapter's Continuing Education Committee, and is currently Chair Elect of the Continuing Education Committee. She had participated in the SNMMI Leadership Academy held in January 2015, and has also been involved in the SNMMI-TS Nuclear Medicine Week Task Force, and SNMMI-TS Program Committee. She also serves on the Nuclear Medicine Technology Certification Board as one of the Board of Directors under the following elected committees: Disciplinary Committee; Educator Outreach Committee; Examination Committee; Nominating Committee; Publications Committee; Task Analysis Committee, and also under the Subgroup: Radiopharmacy.

Krissy resides in Ohio with her husband and two children. She is an avid sports fan that supports the Cleveland Indians, and of course, the Ohio State Buckeyes. In her free time, she enjoys working on home renovation projects, and spending time with her family.

Jason L.J. Dearling, PhD



Jason is currently an Instructor in Radiology at Harvard Medical School and a Research Associate at Boston Children's Hospital (BCH). He received his bachelor's degree in biotechnology from University College, London in 1995 and then worked with Dr. Philip Blower on the structure-activity relationships of copper-essential complexes and how this affected cell uptake for his PhD thesis. In 1998 he moved to the Cancer Research UK Targeting and Imaging Laboratory at the Royal Free and University College Medical School, London. This group develops antibody-based cancer therapies, and Jason worked on the optimization of radioimmunotherapy (RIT), in particular on overcoming the challenges presented by the tumor microenvironment. In 2005, Jason moved to Boston to join Dr. Alan Packard's Radiochemistry and Radiopharmaceutical Development Laboratory at BCH. Work at BCH has a pediatric slant, and current projects include detection of response to therapy in neuroblastoma using ^{64}Cu -labeled antibodies, which was funded by the Society for Pediatric Radiology with Jason as PI.

During Jason's career his research has ranged from investigating the tissue localization of ^{18}F FDG in cardiac and tumor tissue in relation to relevant biological parameters, to studying the movement of antibodies within tumors during imaging, and using targeted nanoparticles to improve delivery of therapeutic siRNA to sites of colitis.

In addition to his experimental work and peer-reviewed publications, Jason has published several invited reviews and book chapters, is a journal editor, grant reviewer and ad hoc manuscript reviewer for more than 20 journals in the field. Jason is an active member of the SNMMI having organized continuing education sessions, and is a member of the CMIIT Education Task Force.

If given the opportunity to serve as a member of the RPSC Board of Directors, Jason will work to increase membership by becoming a member of the RPSC Membership Committee and will focus on improving education and communication within the community.

Umesh Gangadharmath, PhD




Umesh Gangadharmath, PhD is currently an Assistant Professor at the Department of Medical and Molecular Pharmacology and Director of Biomedical Cyclotron Facility at University of California Los Angeles, Los Angeles. Dr. Umesh Gangadharmath also holds a scientific advisory position and the Director of Radiochemistry at Optimal Tracers, a not-for-profit division of Northern California PET Imaging Center. Optimal Tracers is a radiochemistry service facility that provides clinical and pre-clinical radiotracers to the exact specifications of their customers in both academic and commercial settings. Dr. Gangadharmath brings with him an extensive amount of radiochemistry and radiopharmaceutical experience both in academic and commercial settings. Umesh has designed and synthesized novel

radiopharmaceuticals for use in positron emission tomography (PET) imaging of oncology, cardiology and neurological targets, including a marker for hypoxia (18F-HX4), apoptosis (18F-CP18) and markers for Tau (18F-T808/T807/AV1451). He was an early adopter of 'click chemistry' as a tool to accelerate PET radiopharmaceutical development. Umesh has extensive experience in drug design for PET Imaging, radiosynthesis process optimization and has established PET tracer manufacturing sites globally (US, EU and Asia) to support PET imaging-based clinical trials.

He received his M.Sc and Ph.D in Inorganic chemistry from Karnatak University Dharwad, India in 2002 and was a former post-doctoral student at the University of California, Los Angeles in 2005. He is named as a co-inventor on 17 patents and has more than 20 peer-reviewed papers. He is serving as a USP Radioactive Drugs Expert Panel Member. He is a participating member of the Editorial Advisory Board for Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography (publisher Wiley). He is a reviewer for Tetrahedron Letters and Applied Radiation and Isotopes. He is also a member of ISRS. He has been an active member of SNMMI and has reviewed abstracts for the SNM Annual Meeting for the past couple of years.

Dr. Umesh Gangadharmath has been actively involved in radiopharmaceutical research and development for the past 10 years. His major research interests are in developing new small molecule radiotracers and radiolabeled peptides for PET molecular imaging. He is interested in working with pharma and academic institutions to facilitate Industry-University partnership. His current position at the University of Los Angeles, Los Angeles is focused on the clinical research and clinical development of new PET tracers as well as cGMP manufacturing of existing clinical PET agents. He is the director of their radiochemistry facility and he manages the cyclotron as well as the cGMP PET facility.

Hao Hong, PhD.



Hao Hong is currently an Assistant Professor of Radiology at the University of Michigan Health Systems. He received a BS degree (2002) and a PhD degree (2008) from Nanjing University, China, both in Biochemistry. Between 2008 and 2013, Dr. Hong did his post-doctoral research in the laboratory of Prof. Weibo Cai at the University of Wisconsin - Madison. In September 2014, Dr. Hong joined the University of Michigan in the Department of Radiology as a research faculty. Dr. Hong's research at University of Michigan is primarily focused on: 1) development of angiogenesis-targeted imaging agents; 2) novel image-guidable nanomaterials for cancer-targeted drug delivery; and 3) combinational cancer therapy. The imaging techniques routinely used in his research include positron emission tomography (PET), bioluminescence/fluorescence, magnetic resonance imaging (MRI), photoacoustic imaging (PAI), and ultrasound.

Dr. Hong has authored >90 peer-reviewed articles, 8 book chapters, and >80 conference abstracts. His publications have been cited >3,200 times with an H-index of 31. He has co-edited 1 book with Dr. Weibo Cai, guest-edited 2 special topic issues for scientific journals, and given >50 talks. Dr. Hong has received many awards, including the Susan G. Komen Post-Doctoral Fellowship (2009-2011), SNMMI Berson-Yalow Award (2012), Siemens Novel Application Image of the Year (2nd Place, 2013), CASNMMI Young Researcher Award (1st Place, 2013), among many others. Dr. Hong has served on the Editorial Board of 4 scientific journals, performed peer review for >30 journals, and participated in many grant review panels (National Science Center – Poland, Swiss National Science Foundation, Shota Rustaveli National Science Foundation, etc.). He is currently the Executive Editor of the American Journal of Nuclear Medicine and Molecular Imaging (<http://www.ajnmni.us>).

Dr. Hong has been an active member of several scientific societies such as SNMMI and WMIC, and he considers SNMMI as his home society. Dr. Hong has actively participated in SNMMI Annual meetings such as organizing and moderating several Continuing Education sessions. If elected as Board member of RPSC, he will be fully committed to help the RPSC move into the new year with new goals and initiatives, advance the field of radiopharmaceutical sciences and molecular imaging, train the next generation of radiopharmaceutical and molecular imaging scientists, and recruit new members to RPSC.

Serge K. Lyashchenko, PharmD




Being a clinical radiopharmacist, Dr. Lyashchenko is responsible for development, clinical translation, and quality assurance of radiopharmaceuticals manufactured for human use under Current Good Manufacturing Practices (cGMP) conditions and in full compliance with USP and FDA regulations and guidance. Dr. Lyashchenko oversees the production and release of all radiopharmaceuticals produced at the MSK Radiochemistry and Molecular Imaging Probe Core Facility, as well as hyperpolarized agents produced under cGMP conditions using the Diamond Hyperpolarizer. He is a certified nuclear pharmacist with extensive radiopharmaceutical clinical research experience, and has

received hyperpolarized MR training as a “spin pharmacist” at UCSF.

Dr. Lyashchenko has taken the lead role in the rapidly expanding the field of radiopharmacy, with focus on molecular imaging agent development, clinical translation, manufacture, and characterization.

He was also part of the leadership team that planned and designed the MSK Hyperpolarizer Suite as well as the GMP Manufacturing and Dispensing Suite within the MSK Radiochemistry and Molecular Imaging Probes Core Facility, ensuring the continued expansion and support of the Molecular Imaging Program at MSK.

Jian Q. (Michael) Yu, MD, FRCPC



Dr. Yu is the Chief of Nuclear Medicine and PET Services, in the Department of Diagnostic Imaging, Fox Chase Cancer Center in Philadelphia, Pennsylvania. He served in this position since 2005. Dr. Yu completed his residency training in both Nuclear Medicine at MCP-Hahnemann University Hospital in Philadelphia, and the Hospital of University of Pennsylvania (HUP), serving as chief resident in the Nuclear Medicine at both places in his senior years. He then completed his PET fellowship at the Hospital of University of Pennsylvania (HUP) and became the chief fellow. He did an additional Pediatric Nuclear Medicine Fellowship at Children's Hospital of Philadelphia (CHOP) before joining the faculty practice of Fox Chase Cancer Center, a member

institution of National Comprehensive Cancer Network (NCCN) and one of the NCI designated comprehensive cancer centers.

Dr. Yu is board certified by the American Board of Nuclear Medicine and by the Royal College of Physicians and Surgeons of Canada in the specialty of Nuclear Medicine, and is a Fellow of Royal College of Physicians of Canada (FRCPC). He is also certified in Bone Densitometry by the International Society for Clinical Densitometry.

He is an active committee member of various groups of the Society of Nuclear Medicine. He is the member of several professional organizations including American College of Radiology, World Molecular Imaging Society, American College of Nuclear Medicine (ACNM), and American Society of Clinical Oncology (ASCO). He is a regular reviewer of Clinical Nuclear Medicine (CNM), Journal of Nuclear Medicine (JNM), and several other journals. He is editorial board member of CNM, PET Center of Excellence Newsletter, and American Journal of Nuclear Medicine and Molecular Imaging. Dr. Yu published over 70 peer reviewed papers and book chapters. He is the site PI of several ACRIN (American College of Radiology Imaging Network) trials, and many other clinical research studies. He is a committee member of Experimental Imaging Science Committee in ACRIN, now biomarker committee in ECOG-ACRIN. He is the principal investigator for several phase 0 clinical trials involving novel radioactive PET tracers to detect hypoxia (HX-4, VM4), angiogenesis (RGD-K5), apoptosis (CP-18) and Alzheimer's Disease. He received Fellowship awards from both American College of Nuclear Physicians and American College of Nuclear Medicine in 2009. He was ACNM's Treasurer for 2013, and Secretary for 2014.

For more information on the RPSC, please visit the [website](#) .